1. USP39 stabilizes β-catenin by deubiquitination and suppressing E3 ligase TRIM26 pre-mRNA maturation to promote HCC progression
   Weiwei Wang et al, 2023, Cell Death & Disease CrossRef
2. Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice
   Kenta Motomura et al, 2023, Cancers CrossRef
3. Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations
   Tomoko Aoki et al, 2023, Liver Cancer CrossRef
4. PD-1/PD-L1 and DNA Damage Response in Cancer
   Mateusz Kciuk et al, 2023, Cells CrossRef
5. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
   Anand V. Kulkarni et al, 2023, eClinicalMedicine CrossRef
6. Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma
   Nobuaki Ishihara et al, 2024, Hepatology Research CrossRef
7. Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma
   Stefania De Lorenzo et al, 2022, Cancers CrossRef
8. Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
   Ji Won Han et al, 2023, International Journal of Molecular Sciences CrossRef